You are being directed to ZacksTrade, a division of Zacks & Company and licensed broker-dealer. ZacksTrade and Zacks.com are separate but affiliated companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.

If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.

OK Cancel

Recent Quotes

No Recent Quote currently available

My Portfolio

My Portfolio Tracker

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today.

Zacks #1 Stocks on the Move 08/29/2014

Company Name Symbol %Change
UNITED THERA UTHR
28.51%
P L C SYSTEM PLCSF
27.14%
INUVO INC INUV
9.09%
TRIQUINT SEM TQNT
6.52%
RENESOLA LTD SOL
6.23%
Bacterial Partnering Terms and Agreements

Print Share

Dec 20, 2012 (M2 PRESSWIRE via COMTEX) -- Research and Markets (http://www.researchandmarkets.com/research/c4l56z/bacterial) has announced the addition of the "Bacterial Partnering Terms and Agreements" report to their offering. The Bacterial Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the bacterial partnering deals and agreements entered into by the worlds leading healthcare companies. The report provides a detailed understanding and analysis of how and why companies enter bacterial partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors bacterial technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. Understanding the flexibility of a prospective partner?s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered ? contract documents provide this insight where press releases do not. This report contains over 1,000 links to online copies of actual bacterial deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner?s flexibility on a wide range of important issues, many of which will have a significant impact on each party?s ability to derive value from the deal. The report also includes numerous tables and figures that illustrate the trends and activities in bacterial partnering and dealmaking since 2007. In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of bacterial technologies and products. In Bacterial Partnering Terms and Agreements, available deals and contracts are listed by: - Headline value - Upfront payment value - Royalty rate value - Stage of development at signing - Deal component type - Technology type - Specific therapy indication - Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. Company profiles - Abbott - Actavis - Actelion - Allergan - Amgen - Aspen Pharmacare - Astellas - AstraZeneca - Baxter International - Bayer - Biogen Idec - Boehringer Ingelheim - Bristol-Myers Squibb - Celgene - CSL - Daiichi Sankyo - Dainippon Sumitomo - Eisai - Eli Lilly - Endo Pharmaceuticals - Forest Laboratories - Galderma - Gilead Sciences - GlaxoSmithKline - Grifols - Hospira - Johnson & Johnson - Kyowa Hakko Kirin - Lundbeck - Menarini - Merck & Co - Merck KGaA - Mitsubishi Tanabe - Novartis - Novo Nordisk - Otsuka - Pfizer - Purdue - Roche - Sanofi - Servier - Shionogi - Shire - Takeda - Teva - Valeant - Warner Chilcott - Watson For more information visit http://www.researchandmarkets.com/research/c4l56z/bacterial

CONTACT: Research and Markets, Laura Wood, Senior Manager. press@researchandmarkets.com Fax from USA: 646-607-1907 Fax from rest of the world: +353-1-481-1716 Sector: Pharmaceuticals (http://www.researchandmarkets.com/categories.asp?cat_id=88&campaign_id=c4l56z), Company Reports (http://www.researchandmarkets.com/categories.asp?cat_id=101&campaign_id=c4l56z)

((M2 Communications disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.

(C)1994-2012 M2 COMMUNICATIONS

**********************************************************************

As of Sunday, 12-16-2012 23:59, the latest Comtex SmarTrendA? Alert,
an automated pattern recognition system, indicated a DOWNTREND on
04-16-2012 for BAX @ $55.10.

As of Sunday, 12-16-2012 23:59, the latest Comtex SmarTrend Alert,
an automated pattern recognition system, indicated an UPTREND on
03-13-2012 for BMY @ $33.26.

As of Sunday, 12-16-2012 23:59, the latest Comtex SmarTrend Alert,
an automated pattern recognition system, indicated an UPTREND on
01-03-2012 for FRX @ $30.68.

For more information on SmarTrend, contact your market data
provider or go to www.mysmartrend.com

SmarTrend is a registered trademark of Comtex News Network, Inc.
Copyright A? 2004-2012 Comtex News Network, Inc. All rights reserved.

Zacks Research is Reported On:

Zacks Investment Research

is an A+ Rated BBB

Accredited Business.